Results 21 to 30 of about 4,984,276 (289)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Blood, 2022
Key Points • Anti-GARP:TGF-β1 mAb exerts antitumor activity in myeloproliferative neoplasms by selectively blocking Treg-derived TGF-β1.• Targeting Treg functions is feasible and has immune-mediated therapeutic activity in blood cancers.
S. Lecomte, Devreux Julien, Grégoire de Streel, N. van Baren, D. Schröder, Noora Vaherto, Christophe Vanhaver, Christophe Vanderaa, Noémie Dupuis, C. Pecquet, P. Coulie, S. Constantinescu, S. Lucas   +12 more
semanticscholar   +1 more source

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis

Cancers, 2021
Simple Summary Among myeloproliferative neoplasms, primary myelofibrosis (PMF) is considered the paradigm of inflammation-related cancer development. Host genetic variants such as single nucleotide polymorphisms (SNPs) can affect cytokine/chemokine gene ...
E. Masselli, C. Carubbi, Giulia Pozzi, A. Percesepe, R. Campanelli, L. Villani, G. Gobbi, S. Bonomini, G. Roti, V. Rosti, M. Massa, G. Barosi, M. Vitale   +12 more
semanticscholar   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

Correlation between Primary Myelofibrosis and the Association of Portal Thrombosis with Portal-Biliary Cavernoma: US, MDCT, and MRI Features

Journal of Gastrointestinal and Abdominal Radiology, 2021
Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo, Stefania Galassi, Salvatore Merola, Paolo Bonome, Esmeralda Conte, Elsa Iannicelli   +5 more
doaj   +1 more source

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations.
A. Tefferi
semanticscholar   +1 more source

Focus on Osteosclerotic Progression in Primary Myelofibrosis

Biomolecules, 2021
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hematopoietic stem-cell-derived clonal proliferation, leading to bone marrow (BM) fibrosis.
M. Spampinato, C. Giallongo, A. Romano, L. Longhitano, E. La Spina, R. Avola, G. Scandura, I. Dulcamare, V. Bramanti, M. Di Rosa, N. Vicario, R. Parenti, G. Li Volti, D. Tibullo, G. Palumbo   +14 more
semanticscholar   +1 more source

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review

Internal medicine, 2021
Ruxolitinib, a Janus kinase inhibitor, improves symptoms in patients with myelofibrosis. However, its association with the development of opportunistic infections has been a concern.
Asuka Ogai, K. Yagi, Fumimaro Ito, H. Domoto, T. Shiomi, K. Chin   +5 more
semanticscholar   +1 more source

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source